Mouse Models of Stargardt Disease in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Stargardt Disease

Stargardt disease is an inherited macular dystrophy, in most cases caused by biallelic ABCA4 variants.

The transporter's failure to clear retinoid by-products of the visual cycle leads to bisretinoid accumulation in the retinal pigment epithelium and then to loss of pigment epithelium and photoreceptors, centered on the macula.

Stargardt Disease in Experimental Research

Mouse retinas have no macula, so an Abca4-deficient mouse reproduces the biochemical lesion, the lipofuscin accumulation and its consequences for the pigment epithelium rather than the central atrophy the disease is named for.

The degeneration in the mouse is also slower and milder than the human disease. Its severity depends on:

  • The Rpe65 variant carried by the background strain, the methionine-450 form carried by C57BL/6J slowing the visual cycle and reducing bisretinoid accumulation relative to leucine-450 backgrounds
  • Light rearing conditions

Genetic background and light-rearing conditions have to be controlled when phenotypes are compared. Autofluorescence, cone-specific electrophysiology and pigment epithelium measures carry more of the phenotype in a mouse than any measure of central vision.

Mouse Models of Stargardt Disease

The mouse carries most of this work.

Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.

A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.

Published MICRON Research: Stargardt Disease in Mice

This page lists 7 papers from the MICRON literature, published 2012 to 2026, that study Stargardt disease in mice.

Of these publications:

  • 6 studies used mice as the primary Stargardt disease disease model.
  • 1 study used healthy animals to assess pharmacokinetics, drug delivery, or tolerability.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published Stargardt disease research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Electroretinography

Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.

Optical Coherence Tomography

Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.

As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).

Intravitreal Injection / Delivery

Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.

Topical Ophthalmic Drug Delivery

A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.

Fundus Fluorescein Angiography

Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.

This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.

Laser Photocoagulation Models

A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease.

Which MICRON systems and add-ons appear?

Which MICRON systems and add-ons appear?
Instrument Papers
MICRON III 4
MICRON IV 3
Image-Guided OCT 2

Which strains and genetic lines are used?

Which strains and genetic lines are used?
Strain Papers Reported as
C57BL/6J 2
ABCA4−/− 1
BALB/c 1
C57BL/6 1
NOD-SCID 1

What other conditions are recorded on the same papers?

What other conditions are recorded on the same papers?
Disease Papers
Retinal Degeneration (General) 5
Age-Related Macular Degeneration (General) 3
Age-Related Macular Degeneration (Dry/Atrophic) 2
Diabetic Retinopathy 2
Retinal Detachment 2
Retinal Pigment Epithelium Dysfunction 2
Retinitis Pigmentosa (RP) 2
Age-Related Macular Degeneration (Wet/Neovascular) 1
Color Vision Defects 1
Diabetes Mellitus, Type 1 1
Diabetic Retinal Neurodegeneration 1
Epiretinal Membrane 1
Leber Congenital Amaurosis (LCA) 1
Light-Induced Retinal Degeneration 1
Retinal Artery Occlusion 1
Retinal Neovascularization (General) 1
Retinal Vein Occlusion (RVO) 1

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

Which MICRON configurations appear in this work?
MICRON configuration Papers Most frequent techniques recorded alongside
MICRON III 4 Electroretinography (3), Optical Coherence Tomography (2), Topical Ophthalmic Drug Delivery (1)
MICRON IV 3 Optical Coherence Tomography (3), Electroretinography (2), Topical Ophthalmic Drug Delivery (1)
Image-Guided OCT 2 Optical Coherence Tomography (2), Topical Ophthalmic Drug Delivery (1), Electroretinography (1)

The papers

The papers
Year Title Journal Role of focal species MICRON products Links
2026 Crop-OCT: a Fully Integrated Imageomics Pipeline to Identify Regional and Focal Retinopathy in Murine Models bioRxiv Disease model Image-Guided OCT, MICRON IV DOI · reSEARCH
2025 Sustained release of a novel non-fibrate PPARα agonist from microparticles for neuroprotection in murine models of age-related macular degeneration. Journal of Controlled Release Disease model MICRON IV DOI · reSEARCH
2025 Rescue of the Stargardt Disease Phenotype in <i>Abca4</i> Knockout Mice Through Dietary Modulation of the Vitamin A Receptor RBPR2. FASEB bioAdvances Disease model Image-Guided OCT, MICRON IV DOI · reSEARCH
2019 Oral Delivery of the P2Y12 Receptor Antagonist Ticagrelor Prevents Loss of Photoreceptors in an ABCA4-/- Mouse Model of Retinal Degeneration. Investigative Ophthalmology & Visual Science Disease model MICRON III DOI · reSEARCH
2017 Advances in bone marrow stem cell therapy for retinal dysfunction. Progress in Retinal and Eye Research Healthy PK, delivery or tolerability MICRON III DOI · reSEARCH
2012 DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. The Journal of Clinical Investigation Disease model MICRON III DOI · reSEARCH
2012 Increased cone sensitivity to ABCA4 deficiency provides insight into macular vision loss in Stargardt's dystrophy. Biochimica et Biophysica Acta Disease model MICRON III DOI · reSEARCH

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.

Last built 2026-11-10 from content tag hubs-content-2026-11-10 (ae06cfc); fact-sheet run sheets-20261110T111119Z. About these hubs Back to top